Rybelsus for Weight Loss: Evidence, Eligibility, Coverage
Rybelsus is not FDA approved for weight loss. It is approved for type 2 diabetes and heart risk. Wegovy, with the same ingredient, is approved for weight loss. In STEP 1, people on Wegovy lost 14.9% of body weight on average, vs 2.4% on placebo.
- For weight loss
- Not an approved use
- Active ingredient
- semaglutide
- How it is taken
- daily tablet
- Best result (STEP 1)
- 14.9% weight loss
Rybelsus: key facts
About 1 week is the half-life. After 7 d, half is gone, and once five half-lives have passed (35 d) about 3% remains.
For type 2 diabetes, the PIONEER 1 trial ran 26 weeks. Weight loss was 3.7 kg, compared with 1.4 kg on placebo.
The maker's price page provides monthly list price and self-pay offers in US dollars.
Sources: FDA label (DailyMed), healthsystemtracker.org, Novo Nordisk pricing, Novo Nordisk.
Who can use it?
| Who sets the rule | Who can use it? |
|---|---|
| FDA label | When used with diet and exercise, it helps adults with type 2 diabetes lower blood sugar. |
| FDA label | Heart attack, stroke and heart-related death become less likely in high-risk adults with type 2 diabetes who take it. |
| Typical commercial plan (Aetna policy) | BMI 30 or higher |
| Typical commercial plan (Aetna policy) | BMI 27 or higher with a weight-related condition |
| Typical commercial plan (Aetna policy) | first, a program of diet and activity for 6 months |
Sources: FDA label (DailyMed), aetna.com.
Weight loss trial findings
No trial has tested Rybelsus in this group. The trials cover other brands that use an identical ingredient.
| Trial | Medicine | Who took part | Length | People | Main result | Comparison |
|---|---|---|---|---|---|---|
| STEP 1 |  Wegovy | Adults with obesity or overweight, without diabetes | 68 weeks | 1,961 | 14.9% weight loss | 2.4% on placebo |
| OASIS 4 | Wegovy | Adults with obesity or overweight, without diabetes | 64 weeks | 307 | 13.6% weight loss | 2.4% on placebo |
Trial information comes from STEP 1 (FDA label (DailyMed)).
What changes for weight loss?
| What changes | What the label says |
|---|---|
| Acute Pancreatitis | Can cause inflammation of the pancreas. If severe stomach pain does not go away and may spread to your back, stop taking it and get care. |
| Acute Gallbladder Disease | Gallstones and gallbladder inflammation can happen. Report pain on the upper right side of the belly, fever, or yellow skin or eyes. |
Taken from the FDA labels: FDA label (DailyMed).
Label warnings come from FDA label (DailyMed).
Weight loss coverage
Medicare Part D excludes a GLP-1 that is used only for weight loss.
Prior authorization is standard in places where Medicaid covers weight-loss GLP-1s.
Sources: humana.com, KFF.
Other weight loss choices
| Medicine | For weight loss | How it is taken | Trial result |
|---|---|---|---|
| Wegovy | FDA approved | weekly injection or daily tablet | 14.9% weight loss |
 Zepbound | FDA approved | weekly injection | 20.9% weight loss |
 Foundayo | FDA approved | daily tablet | 11.1% weight loss |
 Saxenda | FDA approved | daily injection | 7.4% weight loss |
| Rybelsus | Not an approved use | daily tablet | Not listed |
 Ozempic | Not an approved use | weekly injection | Not listed |
 Mounjaro | Not an approved use | weekly injection | Not listed |
 Trulicity | Not an approved use | weekly injection | Not listed |
 Victoza | Not an approved use | daily injection | Not listed |
| Byetta | Not an approved use | twice-daily injection | Not listed |
Sources: FDA label (DailyMed).
Questions for your prescriber
- Does my weight meet the label's rule, and does my plan have any added rule of its own?
- Which weight-related conditions listed in my record qualify?
- How much weight should I expect to lose once the first year ends?
- If I stop taking it, what should I expect?
Read the complete Rybelsus prescribing information on DailyMed.